van Hout, B A <br/><br/>
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.  [electronic resource] 

 -  European heart journal  Apr 1998 
 - D59-66 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0195-668X 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Angioplasty, Balloon, Coronary--economics<br/>Antibodies, Monoclonal--economics<br/>Coronary Disease--drug therapy<br/>Cost-Benefit Analysis<br/>Humans<br/>Immunoglobulin Fab Fragments--economics<br/>Platelet Aggregation Inhibitors--economics<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Randomized Controlled Trials as Topic<br/>Treatment Outcome<br/>United States